Ranbaxy Must Withdraw Several ANDAs Under DoJ Consent Decree; Will Lose 180-Day Exclusivity On Others
This article was originally published in The Pink Sheet Daily
Three executives are named in the complaint, which the government calls “groundbreaking in its international reach.” The complaint cites GMP problems at four Ranbaxy facilities, three in India and one in New York, and says the company submitted false data in drug applications.
You may also be interested in...
Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations
Ranbaxy Laboratories said it has signed a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation involving GMP violations and data integrity issues at its Indian facilities.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.